Search results
Results from the WOW.Com Content Network
Astellas Pharma office in Canada. Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
(Reuters) - Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues ...
Astellas Institute for Regenerative Medicine is a subsidiary of Astellas Pharma located in Marlborough, Massachusetts, US, developing stem cell therapies with a focus on diseases that cause blindness. It was formed in 1994 as a company named Advanced Cell Technology, Incorporated (ACT), which was renamed to Ocata Therapeutics in November 2014. [3]
The top 5 best selling pharmaceuticals 2015–2019. Sales in billion USD. [1] ... Company Sales (USD millions/year) ... Astellas Pharma US: Overactive bladder: Feb-2000:
Astellas Pharma, a multinational pharmaceutical company of Japan, and part of the Mitsubishi UFJ Financial Group conglomerate. Pages in category "Astellas Pharma" The following 27 pages are in this category, out of 27 total.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from his new tariffs on Chinese imports, as they join big pharma lobbyists who have ...